Atlas Trials

Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

Clinical trial NCT00256828 · COMPLETED

Trial details

NCT number
NCT00256828
Sponsor
Clinical Trial Agency of HIV Study Group
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
HIV Infections
Start date
2004-06-01
Enrollment
360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.